Medicare is launching a pilot program to cover GLP-1 weight loss drugs solely for obesity treatment, marking a significant policy shift. The initiative targets enrollees who meet specific weight-related health criteria, but it does not apply to those using the drugs for diabetes. Eligibility requires a body mass index of 30 or higher, or 27 plus at least one weight-related condition like high blood pressure.
The program covers popular medications such as Wegovy and Zepbound, but not Ozempic or Mounjaro, which are approved for diabetes. Costs will vary based on each enrollee’s Part D prescription drug plan, with some facing copays or coinsurance. Monthly out-of-pocket expenses could range from under $50 to several hundred dollars, depending on coverage tiers.
Enrollees must also participate in a structured lifestyle intervention program, including diet and exercise counseling. The pilot is set to run for five years, with data collected to evaluate long-term outcomes. Experts caution that supply shortages may persist, potentially delaying access for new patients.
Medicare previously excluded weight loss drugs from coverage, citing cost concerns and lack of evidence on long-term benefits. This pilot responds to growing demand and recent studies showing significant health improvements. The program does not cover the drugs for cosmetic weight loss, only for diagnosed obesity.
Patients should consult their doctors to confirm medical necessity and secure prior authorization from their plan. The Centers for Medicare and Medicaid Services will monitor adherence and effectiveness throughout the pilot. Early reports suggest that many Part D plans have already updated their formularies to include these drugs.
Analysts estimate that Medicare spending on GLP-1s could reach billions annually if the pilot expands. The program’s success may influence private insurers and employer-sponsored plans to follow suit. For now, eligible beneficiaries should act quickly, as enrollment windows and plan limits apply.
Critics argue that the high costs could strain Medicare’s budget without guaranteed long-term health gains. Supporters point to improved quality of life and reduced obesity-related complications. The pilot represents a cautious but consequential step in federal health policy.
